---
title: "Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295589045.md"
description: "LifeSci Capital analyst Charles Zhu maintained a Buy rating on Protara Therapeutics, lowering the price target from $26 to $20. The decision reflects confidence in the company's strategic trial shift for TARA-002, which aims to accelerate data generation and broaden commercial opportunities. Zhu also cited a solid balance sheet with cash runway into 2028 and clear clinical milestones as key factors supporting the favorable risk-reward profile despite the reduced valuation."
datetime: "2026-08-11T23:05:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295589045.md)
  - [en](https://longbridge.com/en/news/295589045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295589045.md)
generator: "portal-rs"
---

# Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics, reducing the price target to $20.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Charles Zhu has given his Buy rating due to a combination of factors, including Protara’s strategic shift in trial design that is intended to accelerate and broaden clinical data generation for TARA-002 in non-muscle invasive bladder cancer. By converting ADVANCED-3 into an open-label exploratory study that spans both BCG-naive and BCG-exposed high‑grade populations, management is positioning the asset for a more expansive commercial opportunity at the time of a potential BCG‑unresponsive launch.

Zhu also emphasizes the company’s refined clinical milestones and solid balance sheet, noting that Protara has laid out clear timelines for key readouts across ADVANCED-2, STARBORN-1, and THRIVE-3 while maintaining cash runway into 2028. Coupled with management’s confidence in achieving a clinically meaningful complete response rate in BCG-unresponsive disease and the prospective compendia listing that could unlock access to roughly 20,000 U.S. patients, he sees a favorable risk‑reward profile that justifies a Buy rating despite revising the price target to $20 from $26.

### Related Stocks

- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)

## Related News & Research

- [Protara Therapeutics to Present at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298359574.md)
- [Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen](https://longbridge.com/en/news/295992564.md)
- [Permian Resources Corporation $PR Shares Acquired by Readystate Asset Management LP](https://longbridge.com/en/news/298197803.md)
- [PR Newswire - Service Test Notice](https://longbridge.com/en/news/297682216.md)
- [Global PR Agency, Genius PR, Rebrands to Reflect Growth Across Crypto, AI, and O-1 and EB-1 Visa PR](https://longbridge.com/en/news/297960123.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**